Boundless Bio Inc 2024年度报告

Certain portions of the registrant’s definitive proxy statement for the 2025 annual meeting of stockholders to be filed with the Securities and Exchange Commission not later than120 days after the end of the fiscal year covered by this report are incorporated by reference into Part III of this report. Tableof Contents PART I Item 1.BusinessItem 1A.Risk FactorsItem 1B.Unresolved Staff CommentsItem 1C.CybersecurityItem 2.PropertiesItem 3.Legal ProceedingsItem 4.Mine Safety Disclosures PART II Item 5.Market for Registrant’s Common Equity, Related Stockholder Matters, and Issuer Purchases of EquitySecurities91Item 6.[Reserved]92Item 7.Management’s Discussion and Analysis of Financial Condition and Results of Operations93Item 7A.Quantitative and Qualitative Disclosures About Market Risk102Item 8.Financial Statements and Supplementary Data102Item 9.Changes in and Disagreements with Accountants on Accounting and Financial Disclosure102Item 9A.Controls and Procedures103Item 9B.Other Information103Item 9C.Disclosure Regarding Foreign Jurisdictions that Prevent Inspections104 PART III Item 10.Directors, Executive Officers, and Corporate Governance105Item 11.Executive Compensation105Item 12.Security Ownership of Certain Beneficial Owners and Management and Related Stockholder Matters105Item 13.Certain Relationships and Related Transactions, and Director Independence105Item 14.Principal Accountant Fees and Services105 PART IV Item 15.Exhibits and Financial Statement Schedules106Item 16.Form 10-K Summary107 PART I SPECIAL NOTE REGARDING FORWARD-LOOKING STATEMENTS AND MARKET AND INDUSTRY DATA This Annual Report on Form 10-K contains forward-looking statements within the meaning of Section 27A of the SecuritiesAct of 1933, as amended (the Securities Act) and Section 21E of the Securities Exchange Act of 1934, as amended (the ExchangeAct). All statements other than statements of historical facts contained in this report are forward-looking statements, includingstatements regarding our future results of operations and financial position, our use of the net proceeds from the initial publicoffering of our common stock, the sufficiency of our cash position to fund operations and achievement of milestones, includingclinical data readouts and regulatory filings, the timing and likelihood of success, plans, and objectives of management for futureoperations, business strategy, research and development plans, the anticipated timing, costs, design, and conduct of our ongoingand planned clinical trials and preclinical studies for our extrachromosomal DNA (ecDNA) directed therapeutic candidates(ecDTx), ecDNA diagnostic, our other discovery programs, the timing of expected data readouts, the potential safety andtherapeutic benefits of our ecDTx, the potential addressable patient populations for our ecDTx, the timing and likelihood ofdevelopment candidate nominations from our discovery-stage programs, the timing and likelihood of regulatory filings andapprovals for our ecDTx, expected regulatory approval pathways for our ecDTx and any ecDNA diagnostic, our ability tocommercialize our ecDTx, if approved, the pricing and reimbursement of our ecDTx, if approved, potential competition for ourecDTx, the potential to develop future ecDTx, the potential benefits of strategic collaborations and our intent to enter into anystrategic arrangements, our intellectual property and other market exclusivity strategies. In some cases, you can identify forward-looking statements by terms such as “anticipate,” “believe,” “contemplate,”“continue,” “could,” “estimate,” “expect,” “intend,” “may,” “plan,” “potential,” “predict,” “project,” “should,” “would,” “target,”or “will” or the negative of these terms or other similar expressions. Our forward-looking statements are only predictions. We havebased our forward-looking statements largely on our current expectations and projections about future events and financial andother trends that we believe may affect our business, financial condition, and results of operations based upon information availableto us as of the date of this report. Such information may be limited or incomplete. Forward-looking statements in this report speakonly as of the date of this report and are subject to several risks, uncertainties, and assumptions, including those described in Part I,Item 1, “Business,” and Item 1A, “Risk Factors,” and Part II, Item 7, “Management’s Discussion and Analysis of FinancialCondition and Results of Operations.”The events and circumstances reflected in our forward-looking statements may not beachieved or occur and our actual results, performance, or achievements could differ materially from those expressed or implied byour forward-looking statements. Moreover, we operate in an evolving environment. New risk factors and uncertainties may emergefrom time to time, and it is not possible for management to predict all risk factors and uncertainties. Because forward-lookingstatements are inherentl